Intra-Cellular Therapies (ITCI) Misses Q2 EPS by 5c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q2 EPS of ($0.85), $0.05 worse than the analyst estimate of ($0.80). Revenue for the quarter came in at $20 million versus the consensus estimate of $19.44 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Freedom Broker Starts Copart (CPRT) at Buy
• Trupanion (TRUP) Reiterated at Hold by Stifel After 'Eight Straight Years of Share Losses'